Lzheimer’s illness: final results from a randomized, controlled trial. J Alzheimers Dis 2012, 31:225?36. 11. Black R, Greenberg B, Ryan JM, Posner H, Seeburger J, Amatniek J, Resnick M, Mohs R, Miller DS, Saumier D, Carrillo MC, Stern Y: Scales as outcome measures for Alzheimer’s illness. Alzheimers Dement 2009, five:324?39. 12. Folstein MF, Folstein SE, McHugh PR: `Mini-mental state’. A sensible process for grading the cognitive state of sufferers for the clinician. J Psychiatr Res 1975, 12:189?98. 13. McKhann G, Drachman D, Folstein M, Katzman R, Price tag D, Stadlan EM: Clinical diagnosis of Alzheimer’s illness: report in the NINCDS-ADRDA26.27.28. 29.Work Group under the auspices of Department of Well being and Human Solutions Activity Force on Alzheimer’s Disease. Neurology 1984, 34:939?44. Burke WJ, Roccaforte WH, Wengel SP: The short type of the Geriatric Depression Scale: a comparison using the 30-item form. J Geriatr Psychiatry Neurol 1991, 4:173?78. Rosen WG, Mohs RC, Davis KL: A new rating scale for Alzheimer’s illness. Am J Psychiatry 1984, 141:1356?364. Wechsler D: Wechsler Memory Scale Manual. Psychological Corp.: San Diego, CA; 1987. Van der Elst W, Van Boxtel MP, Van Breukelen GJ, Jolles J: The Notion Shifting Test: adult normative data. Psychol Assess 2006, 18:424?32. van der Elst W, van Boxtel MP, van Breukelen GJ, Jolles J: The Letter Digit Substitution Test: normative data for 1,858 wholesome participants aged 24?1 in the Maastricht Aging Study (MAAS): influence of age, education, and sex. J Clin Exp Neuropsychol 2006, 28:998?009. Lezak MD, Howieson DB, Loring DW: Neuropsychological Assessment. New York: Oxford University Press; 2004. Galasko D, Bennett D, Sano M, Ernesto C, Thomas R, Grundman M, Ferris S: An inventory to assess activities of every day living for clinical trials in Alzheimer’s disease. The Alzheimer’s Disease Cooperative Study. Alzheimer Dis Assoc Disord 1997, 11:S33 39. Morris JC: The Clinical Dementia Rating (CDR): present version and scoring guidelines. Neurology 1993, 43:2412?414. Berg L: Clinical Dementia Rating (CDR). Psychopharmacol Bull 1988, 24:637?39. Doraiswamy PM, Kaiser L, Bieber F, Garman RL: The Alzheimer’s Illness Assessment Scale: evaluation of psychometric properties and patterns of cognitive decline in multicenter clinical trials of mild to moderate Alzheimer’s illness. Alzheimer Dis Assoc Disord 2001, 15:174?83. Wurtman RJ, Cansev M, Sakamoto T, Ulus IH: Use of phosphatide precursors to promote synaptogenesis. Annu Rev Nutr 2009, 29:59?7. Selkoe DJ: Deciphering the genesis and fate of amyloid beta-protein yields novel therapies for Alzheimer disease. J Clin Invest 2002, 110:1375?381.3-Chloro-5H-pyrrolo[2,3-b]pyrazine site Terry RD, Masliah E, Salmon DP, Butters N, DeTeresa R, Hill R, Hansen LA, Katzman R: Physical basis of cognitive alterations in Alzheimer’s illness: synapse loss could be the key correlate of cognitive impairment.4-Bromo-3,6-dichloropyridazine uses Ann Neurol 1991, 30:572?80.PMID:33539848 Sperling RA, Aisen PS, Beckett LA, Bennett DA, Craft S, Fagan AM, Iwatsubo T, Jack CR Jr, Kaye J, Montine TJ, Park DC, Reiman EM, Rowe CC, Siemers E, Stern Y, Yaffe K, Carrillo MC, Thies B, Morrison-Bogorad M, Wagster MV, Phelps CH: Toward defining the preclinical stages of Alzheimer’s illness: suggestions in the National Institute on Aging lzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s illness. Alzheimers Dement 2011, 7:280?92. DeKosky ST, Scheff SW: Synapse loss in frontal cortex biopsies in Alzheimer’s disease: correlation with cognitive severity. Ann Neurol 1990,.